BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and ...

For columnist Alliah Czarielle's husband, hemophilia demands a slow and intentional life. It's not glamorous, but there is much hidden value.

ATLAS trial investigator Guy Young, MD, Children's Hospital Los Angeles and University of Southern California Keck School of ...

Adults with hemophilia who switched from standard to extended half-life replacement treatment products had fewer bleeding episodes.

PDF for Biology from the official Rajasthan Board website. Access chapter-wise details for Biology with the link to download ...

A rare inherited genetic blood disorder that mostly affects men, hemophilia is on the rise, with more than a million men ...

Pfizer (PFE) stock in focus as its hemophilia drug Hympavzi succeeds in a Phase 3 trial. Read more here.

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

NEW YORK, June 26, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents ...

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors Study demonstrates superiority, showing both statistically significant and clinically ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress ...